An earnings season to savour where the rewards keep coming

Jun Bei Liu talks to the AFR about the earnings season just gone, and while the path forward is still unclear, one thing for certain is that recovery is on its way.

Jun Bei Liu

An earnings season to savour where the rewards keep coming

August 31, 2020
Jun Bei Liu talks to the AFR about the earnings season just gone, and while the path forward is still unclear, one thing for certain is that recovery is on its way.
Read Transcript

While the path forward is still unclear, one thing for certain is that recovery is on its way. And some of the underperformers could take off.

Many earnings season bears surfaced in July, warning that markets would retest the March low. But we remained optimistic on the basis that earnings expectations were low and government stimulus was effective.

Even so, we were surprised at the extent of sharp share price reactions following some seemingly ordinary results. So, what have we learnt?

The June half had certainly been very tough for many sectors, particularly those directly affected by the pandemic-induced lockdown. With the lockdown still in place in Victoria, companies in these sectors were certainly cautious when guiding to earnings recovery.

For those businesses, it is all about the trajectory of the earnings recovery, as well as capital preservation. With minimal earnings expectations for 2019-20, many of these outperformed meaningfully.

What surprised us though, was that travel names performed particularly strongly despite the more prolonged recovery outlook.

Our view has always been that current market conditions offer ample opportunities to buy some premium assets that are trading at a fraction of their intrinsic value. Sydney Airport, Scentre Group and Ramsay Health Care are some of our favourites in playing the reopening theme.

Investors are paying very little at this point for earnings, and we are comfortable that once the world returns to normal – and it will – these businesses will experience a V-shaped recovery regardless of the economic cycle. In fact, lower interest rates around the world will further underpin their traditional premium to the market.

Most retailers have staged a phenomenal comeback, aided by the stimulus and changing consumption patterns. It would seem that saved overseas travel dollars are now being spent on housing renovation and discretionary items. While many would call this boost to sales temporary, and look to take profits accordingly, our view is that this is too early.

Super-sweet spot

We expect consumers to remain domestically bound at least for the next 10 months before the world is clear of COVID-19.

A positive top-down view should not be translated into a blanket buy of the whole sector. Fundamental research is the critical factor to generate superior returns. In this vein, Super Retail, which owns Supercheap Auto, BCF, macpac and Rebel, operates in the sweet spot of this transition year.

People are travelling more to local camping grounds, and many are now booked out for the Christmas break. What’s more attractive is that Super Retail is trading at only 14 times earnings which is a substantial discount to the ASX industrial earnings multiple of 22 times.

If judged by share prices, it would seem the tech sector has been the biggest beneficiary of the pandemic. The industry on aggregate outperformed the ASX 200 by a staggering 91 per cent off the March lows, and the leaders have done even better, such as Afterpay, which has delivered an astounding nine-fold return since its low in March.

In the past six months, we have reached a critical turning point in technological adoption. The COVID-induced lockdown has pulled forward this inevitable structural shift, with many innovators reporting a doubling of revenue and market share. Rapid growth in this sector means it is now a significant part of the index. Investors can no longer ignore these growing heroes, which in turn will drive more diverse investors into those already blue-chip registers.

Aside from the buy now, pay later leaders we support, our favourite in the sector is Tyro. The company has been severely affected by the COVID-19 lockdown and the current share price represents an extremely attractive entry point to gain exposure to a multi-year structural shift to digital payments.

Tyro has partnerships with most of the big payment companies, including Zip, and it is rapidly expanding into multiple verticals, taking market share from the big banks. When the world returns to normal, this business will have a V-shaped earnings recovery within weeks, unlike other traditional businesses.

As a last word, it’s worth noting the efforts of companies such as Ramsay Healthcare, which stepped up during this once in a century global crisis.

Ramsay took the lead role to tie up with governments around the world to assist with the COVID-19 response effort. It assisted local public hospitals and aged care centres with beds, ventilators and staff. Environmental, social, and corporate governance has been a popular topic of recent times, and efforts such as this should be recognised.

While the path forward is still unclear, one certainty is that recovery is coming. When it does, we are looking at multiple years of earnings growth for many companies that will underpin our equity market.

This article was originally posted in ARF here.

 Licensed by Copyright Agency. You must not copy this work without permission.

While the path forward is still unclear, one thing for certain is that recovery is on its way. And some of the underperformers could take off.

Many earnings season bears surfaced in July, warning that markets would retest the March low. But we remained optimistic on the basis that earnings expectations were low and government stimulus was effective.

Even so, we were surprised at the extent of sharp share price reactions following some seemingly ordinary results. So, what have we learnt?

The June half had certainly been very tough for many sectors, particularly those directly affected by the pandemic-induced lockdown. With the lockdown still in place in Victoria, companies in these sectors were certainly cautious when guiding to earnings recovery.

For those businesses, it is all about the trajectory of the earnings recovery, as well as capital preservation. With minimal earnings expectations for 2019-20, many of these outperformed meaningfully.

What surprised us though, was that travel names performed particularly strongly despite the more prolonged recovery outlook.

Our view has always been that current market conditions offer ample opportunities to buy some premium assets that are trading at a fraction of their intrinsic value. Sydney Airport, Scentre Group and Ramsay Health Care are some of our favourites in playing the reopening theme.

Investors are paying very little at this point for earnings, and we are comfortable that once the world returns to normal – and it will – these businesses will experience a V-shaped recovery regardless of the economic cycle. In fact, lower interest rates around the world will further underpin their traditional premium to the market.

Most retailers have staged a phenomenal comeback, aided by the stimulus and changing consumption patterns. It would seem that saved overseas travel dollars are now being spent on housing renovation and discretionary items. While many would call this boost to sales temporary, and look to take profits accordingly, our view is that this is too early.

Super-sweet spot

We expect consumers to remain domestically bound at least for the next 10 months before the world is clear of COVID-19.

A positive top-down view should not be translated into a blanket buy of the whole sector. Fundamental research is the critical factor to generate superior returns. In this vein, Super Retail, which owns Supercheap Auto, BCF, macpac and Rebel, operates in the sweet spot of this transition year.

People are travelling more to local camping grounds, and many are now booked out for the Christmas break. What’s more attractive is that Super Retail is trading at only 14 times earnings which is a substantial discount to the ASX industrial earnings multiple of 22 times.

If judged by share prices, it would seem the tech sector has been the biggest beneficiary of the pandemic. The industry on aggregate outperformed the ASX 200 by a staggering 91 per cent off the March lows, and the leaders have done even better, such as Afterpay, which has delivered an astounding nine-fold return since its low in March.

In the past six months, we have reached a critical turning point in technological adoption. The COVID-induced lockdown has pulled forward this inevitable structural shift, with many innovators reporting a doubling of revenue and market share. Rapid growth in this sector means it is now a significant part of the index. Investors can no longer ignore these growing heroes, which in turn will drive more diverse investors into those already blue-chip registers.

Aside from the buy now, pay later leaders we support, our favourite in the sector is Tyro. The company has been severely affected by the COVID-19 lockdown and the current share price represents an extremely attractive entry point to gain exposure to a multi-year structural shift to digital payments.

Tyro has partnerships with most of the big payment companies, including Zip, and it is rapidly expanding into multiple verticals, taking market share from the big banks. When the world returns to normal, this business will have a V-shaped earnings recovery within weeks, unlike other traditional businesses.

As a last word, it’s worth noting the efforts of companies such as Ramsay Healthcare, which stepped up during this once in a century global crisis.

Ramsay took the lead role to tie up with governments around the world to assist with the COVID-19 response effort. It assisted local public hospitals and aged care centres with beds, ventilators and staff. Environmental, social, and corporate governance has been a popular topic of recent times, and efforts such as this should be recognised.

While the path forward is still unclear, one certainty is that recovery is coming. When it does, we are looking at multiple years of earnings growth for many companies that will underpin our equity market.

This article was originally posted in ARF here.

 Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by Australian Financial Review, published on Aug 31, 2020. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lancaster sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.